Y-mAbs Therapeutics (NASDAQ:YMAB) launches the rolling submission of its U.S. marketing application seeking approval of omburtamab for the treatment of pediatric patients with CNS/leptomeningeal metastases (cancer has spread to the membranes lining the brain and spinal cord) from neuroblastoma.
Omburtamab is a monoclonal antibody that binds to an immune checkpoint molecule called B7-H3 that is over-expressed in several types of cancer.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.